Introduction: The data on the use of dual biologics are scant, but a topic of current interest. Case Study: In this report, the treatment regimen of a patient with two T helper 2 pathway-related comorbidities, severe asthma, and chronic spontaneous urticaria, was presented. Results: Both urticaria and asthma symptoms of the patient could not be controlled entirely with monotherapy while both diseases could be controlled after omalizumab-mepolizumab dual treatment. No adverse events were observed after 6 months of dual biologics use. Conclusion: This report supports other publications in the literature involving the use of dual biologics and provides a summary of the literature.